High-dose interleukin-2 (HD-IL2) effective in pretreated metastatic renal cell carcinoma (mRCC)
High-dose interleukin-2 (HD-IL2) can be effective in selected patients with metastatic renal cell carcinoma (mRCC) pretreated with VEGF-targeted agents, according to research presented at the European Society for Medical Oncology Symposium on Immuno-Oncology 2014, in Geneva, Switzerland. “Despite the wide and increasing range of therapies available, the management of metastatic renal cell carcinoma remains challenging.…
